NVO : Analysis & Opinions

  1. Bayer Initiates Phase III Study - Analyst Blog

    July 9, 2013
    Bayer initiated a phase III study on BAY 94-9027 in children with hemophilia A.
  2. Glaxo Initiates Phase III Study - Analyst Blog

    July 8, 2013
    GlaxoSmithKline has initiated a phase III study on a subcutaneous formulation of Arzerra
  3. Bayer Announces Positive Phase I Data - Analyst Blog

    July 8, 2013
    Bayer announced positive results from a phase I study on PCCs.
  4. Priority Review for Roche Candidate - Analyst Blog

    July 5, 2013
    Roche's Biologics License Application (BLA) for oncology candidate obinutuzumab (GA101) was recently accepted by the FDA ...
  5. Bayer Progresses with its Cancer Drugs - Analyst Blog

    July 5, 2013
    Bayer and Onyx submitted applications for the approval of Nexavar in the US and the EU.
  6. Data on Roche's Herceptin - Analyst Blog

    July 3, 2013
    Roche recently announced that CHMP in Europe has given a positive opinion on a subcutaneous formulation of Herceptin for ...
  7. Yet Another Setback for Bayer/JNJ's Xarelto - Analyst Blog

    July 2, 2013
    Bayer and Johnson & Johnson received a CRL from the FDA for Xarelto.
  8. Glaxo's Oncology Drugs Get CHMP Nod - Analyst Blog

    July 2, 2013
    The Committee for Medicinal Products for Human Use recommended the approval of Glaxo's Tafinlar and Tyverb.
  9. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  10. Update on Roche's Perjeta - Analyst Blog

    July 2, 2013
    Roche's sBLA for the use of Perjeta before surgery (after diagnosis) in patients suffering from HER2+ early-stage breast ...
  11. Positive Data on Novartis' Xolair - Analyst Blog

    June 28, 2013
    Novartis announced positive results from the phase III GLACIAL study on Xolair.
  12. FDA Accepts Pfizer sNDA - Analyst Blog

    June 26, 2013
    The FDA's decision regarding the Xeljanz label expansion should be out by Feb 2014.
  13. Freeport Resumes Operations at Grasberg Mine - Analyst Blog

    June 26, 2013
    Freeport McMoRan Copper and Gold Inc. announced that PT Freeport Indonesia (PT-FI) has resumed open pit mining and concentrating ...
  14. Glaxo Presents Albiglutide Data - Analyst Blog

    June 25, 2013
    GlaxoSmithKline presented data from five phase III studies on albiglutide
  15. Pfizer Gives Up Stake in Zoetis - Analyst Blog

    June 25, 2013
    Pfizer lowered its outlook for 2013 to reflect the impact of the divestment of the remaining stake in Zoetis.
  16. Breakthrough Status for Novartis Drug - Analyst Blog

    June 25, 2013
    Novartis recently announced that the US Food and Drug Administration (FDA) has granted "Breakthrough Therapy" designation ...
  17. Data from Bayer/JNJ's Xarelto Study - Analyst Blog

    June 25, 2013
    Bayer's announced that it will present data from a Xarelto clinical program.
  18. Allergan Down on FDA Draft Guidelines - Analyst Blog

    June 25, 2013
    The draft guidelines for Restasis bioequivalence, if finalized, could make it easier for generic versions of Restasis to ...
  19. Data on Lilly's Dulaglutide at ADA - Analyst Blog

    June 24, 2013
    Detailed safety and efficacy data on dulaglutide was presented from three phase III AWARD trials at the American Diabetes ...
  20. AstraZeneca/BMY Present Forxiga Data - Analyst Blog

    June 24, 2013
    AstraZeneca and Bristol-Myers Squibb Company announced results from a phase IIa pilot study on Forxiga
  21. Label Updates for Lilly/Boehringer Diabetes Drugs - Analyst Blog

    June 21, 2013
    The companies said that labels for Tradjenta and Jentadueto will contain additional information about the risk of pancreatitis.
  22. AstraZeneca and BMY Drug Disappoints - Analyst Blog

    June 20, 2013
    AstraZeneca and Bristol-Myers announced disappointing top-line data from a phase IV study on Onglyza
  23. Glaxo Gets Offer for Thrombosis Drugs - Analyst Blog

    June 19, 2013
    GlaxoSmithKline announced that Aspen Pharmacare Holdings Limited has offered to buy Glaxo's thrombosis brands
  24. Positive Data on Novartis' Jakavi - Analyst Blog

    June 18, 2013
    Novartis recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase III ...
  25. Encouraging Data on Novartis' Gilenya - Analyst Blog

    June 14, 2013
    Novartis recently presented new data on Gilenya from a phase III study, TRANSFORMS.
  26. Lilly Alzheimer's Study Terminated - Analyst Blog

    June 14, 2013
    The phase II study was voluntarily terminated due to the identification of abnormal liver biochemical tests during routine ...
  27. Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog

    June 13, 2013
    Sanofi announced that the FDA has cleared its quadrivalent formulation of Fluzone
  28. FDA Panel Positive on GSK's Avandia - Analyst Blog

    June 7, 2013
    The FDA panel recently voted in favor of easing safety restrictions related to Glaxo's Avandia.
  29. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  30. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  31. Mylan Extends Biocon Collaboration - Analyst Blog

    February 14, 2013
    Mylan (MYL) extended its three-year old partnership with India-based Biocon Limited. The companies recently signed a definitive ...
  32. Update on Lilly's Tabalumab - Analyst Blog

    February 11, 2013
    Eli Lilly and Company (LLY) recently provided an update on its rheumatoid arthritis candidate, tabalumab. The company said ...
  33. Generics Continue to Hurt Sanofi - Analyst Blog

    February 8, 2013
    Sanofi (SNY) reported fourth quarter 2012 business earnings of 77 cents per American Depository Share (ADS), in line with ...
  34. Sanofi's Diabetes Drug Gets EU Nod - Analyst Blog

    February 7, 2013
    Recently, Sanofi (SNY) received encouraging news with the European Commission (EC) approving its diabetes candidate, Lyxumia ...
  35. Favorable Ruling for Pfizer - Analyst Blog

    February 7, 2013
    Pfizer Inc. (PFE) recently received a favorable ruling in its patent infringement case against Actavis, Inc. (ACT) for Rapamune. ...
  36. Glaxo Bottom Line Misses Again - Analyst Blog

    February 7, 2013
    GlaxoSmithKline (GSK) reported fourth quarter earnings of 57 cents per ADS, missing the Zacks Consensus Estimate of 96 cents ...
  37. SNY/REGN's Zaltrap Approved in EU - Analyst Blog

    February 6, 2013
    Recently Sanofi (SNY) and partner Regeneron Pharmaceuticals Inc. (REGN) received encouraging news with the European Commission ...
  38. AGN Earnings Miss but Guidance Tops - Analyst Blog

    February 5, 2013
    Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 ...
  39. SHPG Reaches Agreement with US Govt - Analyst Blog

    February 5, 2013
    Ireland-based Shire plc (SHPG) recently announced that the company has reached an agreement in principle to resolve the previously ...
  40. Acorda Gets US Army Support - Analyst Blog

    January 25, 2013
    Acorda Therapeutics, Inc. (ACOR) recently announced that it has been awarded a research contract worth $2.67 million by the ...
  41. FDA Approves Novartis' Exjade - Analyst Blog

    January 25, 2013
    Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) has approved Exjade (deferasirox) for the ...
  42. Acorda Provides Guidance - Analyst Blog

    January 8, 2013
    Acorda Therapeutics, Inc. (ACOR) recently disclosed unaudited sales of Ampyra (dalfampridine) extended release tablets, 1 ...
  43. Sanofi Acquires Rolaids Rights - Analyst Blog

    January 8, 2013
    Sanofi's (SNY) US consumer healthcare division, Chattem, Inc., recently announced that it has acquired worldwide rights of ...
  44. FDA Accepts Merck Combo Therapy NDA - Analyst Blog

    January 7, 2013
    Merck (MRK) recently announced that its resubmitted new drug application (NDA) for its ezetimibe and atorvastatin combination ...
  45. Bayer Takes Over Teva Unit - Analyst Blog

    January 7, 2013
    The HealthCare unit of Bayer AG (BAYRY) recently received the necessary regulatory approval from the Federal Trade Commission ...
  46. Encouraging EPS Outlook from Lilly - Analyst Blog

    January 7, 2013
    Late last week, Eli Lilly and Company (LLY) provided its financial guidance for 2013 and commented on its 2012 guidance as ...
  47. Takeda Terminates Amylin Agreement - Analyst Blog

    December 31, 2012
    Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement ...
  48. US Approval for Eliquis - Analyst Blog

    December 31, 2012
    Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news when the US Food ...
  49. NVO's Ryzodeg Approved in Japan - Analyst Blog

    December 28, 2012
    Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg ...
  50. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  51. Raptor Drug FDA Action Date Delayed - Analyst Blog

    December 28, 2012
    Raptor Pharmaceutical Corp. (RPTP) recently announced that the US Food and Drug Administration (FDA) has extended the review ...
  52. Pfizer Signs a Couple of Deals - Analyst Blog

    December 26, 2012
    Pfizer (PFE) recently entered into two deals. While one deal was signed with biopharma company Halozyme Therapeutics, Inc. ...
  53. SNY to Expand Animal Health Business - Analyst Blog

    December 26, 2012
    French pharmaceutical company, Sanofi's (SNY) Animal Health division, Merial, recently announced that it will acquire a privately-held ...
  54. Glaxo/THRX's COPD Candidate Advances - Analyst Blog

    December 20, 2012
    GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced that they have submitted a marketing application to ...
  55. Merck Ties Up with GE Healthcare - Analyst Blog

    December 19, 2012
    Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging ...
  56. Glaxo's Anthrax Drug Gets FDA Nod - Analyst Blog

    December 18, 2012
    GlaxoSmithKline (GSK) recently announced that its inhalational anthrax candidate, raxibacumab, has received US Food and Drug ...
  57. CHMP Negative on Isis' Kynamro - Analyst Blog

    December 17, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  58. Eli Lilly Scraps a Phase III Study - Analyst Blog

    December 17, 2012
    Eli Lilly and Company (LLY) recently announced its decision to scrap one of three pivotal phase III studies being conducted ...
  59. J&J Files NDA for Combo Diabetes Drug - Analyst Blog

    December 14, 2012
    Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently announced the submission ...
  60. Sanofi Presents Positive Results - Analyst Blog

    December 13, 2012
    Sanofi (SNY) recently announced positive results from a phase II trial evaluating the efficacy of its hematology candidate, ...
  61. BMY/ABT Present Oncology Data - Analyst Blog

    December 12, 2012
    Bristol-Myers Squibb Company (BMY) and partner Abbott Laboratories (ABT) recently presented data on their oncology candidate ...
  62. NVO Reports Positive Victoza Data - Analyst Blog

    November 29, 2012
    Novo Nordisk (NVO) recently announced data from the post-hoc analysis of two phase III b studies on Victoza (liraglutide) ...
  63. Sanofi SA and Other Big Movers In Healthcare on November 23, ...

    November 23, 2012
    The market is having a good day so far: the Nasdaq has risen 1.3%; the S&P 500 has moved up 1%; and the Dow is trading up ...
  64. China Petroleum & Chemical Corp Among the NYSE's Biggest Movers ...

    November 23, 2012
    The market is currently up, with the Nasdaq moving up 1.3%, the S&P 500 rising 1%, and the Dow increasing 1%. Formerly run ...
  65. CHMP Positive on Sanofi's Lyxumia - Analyst Blog

    November 21, 2012
    Sanofi (SNY) recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
  66. Alkermes Reverts to Neutral - Analyst Blog

    November 16, 2012
    We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is fairly ...
  67. AZN's Forxiga Gets EU Approval - Analyst Blog

    November 15, 2012
    Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) ...
  68. Novo Nordisk A/S and More Big Movers in Healthcare on November ...

    November 6, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has climbed 0.4% and the Dow is trading up 0.6% so far today. The healthcare ...
  69. Strong Quarter at Novo Nordisk - Analyst Blog

    November 2, 2012
    Novo Nordisk (NVO) reported second quarter 2012 earnings of $1.67 per American Depository Receipt (ADR), up 20.1% from the ...
  70. NYSE Stocks, Including Abbott, Making Big Moves on October 15, ...

    October 15, 2012
    The market is on the rise so far this morning. The Nasdaq has risen 0.3%; the S&P 500 is trading up 0.3%; and the Dow has ...
  71. Merck's MK-3102 Encourages - Analyst Blog

    October 11, 2012
    Merck (MRK) recently presented encouraging phase IIb data on its type II diabetes candidate, MK-3102, at the annual meeting ...
  72. Encouraging Data on J&J Candidate - Analyst Blog

    October 10, 2012
    Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently presented encouraging ...
  73. Back to Neutral on Alkermes - Analyst Blog

    September 18, 2012
    We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current ...
  74. Healthcare Stocks, Including Novo Nordisk A/S, Making Big Moves ...

    September 12, 2012
    The morning has been good for the market. The Nasdaq has moved up 0.1%; the S&P 500 has risen 0.3%; and the Dow has increased ...
  75. Novo Nordisk A/S (ADR) and Other Big Movers In Healthcare

    August 14, 2012
    The Nasdaq has climbed 0.6%, the S&P 500 is up 0.3% and the Dow has risen 0.3%, marking a bad morning for the market. The ...
  76. NVO Candidate to Step into Phase III - Analyst Blog

    June 22, 2012
    Novo Nordisk (NVO) recently announced that it is planning to initiate a phase III global development program, SUSTAIN, for ...
  77. Humana Partners with Novo Nordisk - Analyst Blog

    June 20, 2012
    In a concerted effort to provide better healthcare services to diabetic patients, Humana Inc. (HUM) partnered with Novo Nordisk ...
  78. Use ETFs To Bet On Low Debt Europe

    February 24, 2012
    For investors, betting on the low debtor nations might be the best way to access the region.
  79. 7 Stocks with Fundamental Potential

    December 26, 2011
    These names show increases in dividend payments and cash flow, as well as yearly earnings and revenue. While some of their ...
  80. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  81. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  82. Merck's Penance Has Gone On Long Enough

    October 31, 2011
    Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
  83. Bizarre Baxter Struggle To Grow

    October 26, 2011
    Baxter is a strange, but also compelling, big-cap health-care name.
  84. Investing In The AAA Club

    August 11, 2011
    With the recent debt downgrade, the AAA club has now shrunk to only 15 nations.
  85. More To Merck Than Meets The Eye?

    June 22, 2011
    Merck is set up to exceed low-ball estimates.
  86. Fattening Up A Portfolio While Slimming Down

    June 1, 2011
    With the numbers of overweight and obese people growing globally, investors may want to consider stocks on the front lines ...
  87. Lilly Will Pay Investors For Patience

    April 20, 2011
    Lilly isn't dynamic, but the value is there.
  88. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  89. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  90. Prescribing Healthcare Stocks For Your Portfolio

    January 14, 2011
    Despite the recent bad year, healthcare stocks remain a great long term opportunity.
  91. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  92. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  93. Dark Days In Diabetes

    November 9, 2010
    2010 has been a rough year in the diabetes space.
  94. One More Step For MannKind

    December 4, 2008
    This biotech's inhaled insulin seems to work, but will it sell?
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center